NYSE$GMED

Globus Medical Inc · Q1 2022 earnings

Q1 2022 earnings · · Investor relations

Briefing

Globus Medical's Q1 2022 results were announced, showing a slight increase in worldwide net sales and a decrease in GAAP net income compared to the previous year.

Globus Medical reported a 1.4% increase in worldwide net sales, reaching $230.5 million. GAAP net income decreased by 16.0% to $38.1 million, with diluted EPS at $0.37 and non-GAAP diluted EPS at $0.42. The company reaffirmed its full-year 2022 guidance of $1.025 billion in net sales and non-GAAP diluted earnings per share of $2.10.

  • Worldwide net sales increased by 1.4% to $230.5 million compared to Q1 2021.
  • GAAP net income decreased to $38.1 million, a 16.0% drop from the previous year.
  • GAAP diluted EPS was $0.37, while non-GAAP diluted EPS was $0.42.
  • The company reaffirmed its full-year 2022 guidance with sales target of $1.025 billion and non-GAAP diluted EPS of $2.10.

Headline financials

Total Revenue

$231M

Previous: $227M+1.4%
EPS (adj)

$0.42

Previous: $0.49-14.3%
Adjusted EBITDA

$74.3M

Previous: $80.1M-7.2%
Adjusted EBITDA Margin

32.2%

No prior period
Capital Expenditures

-$20M

Previous: -$13.7M-46.1%
Free Cash Flow

$18.1M

Previous: $31.7M-42.8%
Net Income

$38.1M

Previous: $45.3M-16.0%
Operating Income

$46.4M

Previous: $54.5M-14.9%
Gross Profit

$171M

Previous: $172M-0.5%
Cash & Equivalents

$230M

Previous: $185M+24.3%
Total Assets

$2B

Previous: $1.74B+15.0%
Stock-Based Comp

$8.15M

Previous: $7.7M+5.9%

Revenue & EPS history

Globus Medical · Revenue · Quarterly

$231M

Q1 2022+1.4%vs Q1 2021
Beat estimate in 10 of 16 quarters(63%)
ActualEstimate

Revenue by segment

Globus Medical · $231M total across 2 segments · Q1 2022

  • Musculoskeletal Solutions
    $217M+2.3%
  • Enabling Technologies
    $13.1M-11.9%

Forward guidance

The Company today reaffirmed its full year 2022 guidance of $1.025 billion in net sales and non-GAAP diluted earnings per share of $2.10.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q1 2022

Historical avgQ1 2022

+0.8%

Avg return

Earnings day

+0.7%

Avg return

5 days after

+0.9%

Avg return

30 days after

57%

34 / 60 earnings

Positive

+36.0%

Q3 2025

Best reaction

-23.0%

Q1 2025

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-5.1%-14.6%-10.4%
Q4 2025+4.6%+2.1%-8.8%
Q3 2025+36.0%+37.3%+47.6%
Q1 2025-23.0%-19.7%-17.3%
Q4 2024-4.6%-4.9%-12.5%
Q3 2024+10.7%+8.2%+11.2%
Q2 2024+4.0%+8.0%+4.4%
Q1 2024+22.8%+28.7%+31.6%
Q4 2023+2.2%+4.6%-3.1%
Q3 2023-1.4%-5.1%-2.5%
Q2 2023-5.0%-4.8%-9.1%
Q1 2023+2.9%-0.3%-1.8%
Q4 2022-1.2%-21.9%-29.2%
Q3 2022-4.2%+9.4%+11.5%
Q2 2022+5.4%+6.9%-2.4%
Q1 2022+0.1%+5.2%+0.1%
Q4 2021-3.1%-3.7%+1.3%
Q3 2021+0.2%-4.3%-19.4%
Q2 2021-3.3%-3.0%+1.3%
Q1 2021+3.1%+3.0%-0.9%
Q4 2020-5.7%-5.2%-10.2%
Q3 2020+2.4%+3.5%+16.9%
Q2 2020+18.5%+13.4%+13.3%
Q1 2020+8.1%+0.6%+21.4%
Q4 2019-2.1%-9.7%-29.0%
Q3 2019+3.6%+4.2%+8.2%
Q2 2019+9.9%+6.1%+12.0%
Q1 2019-1.9%-2.0%-11.0%
Q4 2018+0.2%-2.2%-0.3%
Q3 2018-8.7%-9.9%-19.4%
Q2 2018+4.7%+1.7%+3.5%
Q1 2018-3.4%+0.7%+12.6%
Q4 2017+0.5%-1.8%+2.2%
Q3 2017+9.8%+19.7%+24.3%
Q2 2017-5.2%-3.7%-1.7%
Q1 2017+4.9%+1.0%+4.7%
Q4 2016-3.1%-2.1%+2.5%
Q3 2016-5.6%-4.9%+7.1%
Q2 2016-14.3%-11.7%-13.1%
Q1 2016-9.4%
Q4 2015+4.2%
Q3 2015+12.3%
Q2 2015+2.5%
Q1 2015+4.8%
Q4 2014-0.9%
Q3 2014+7.0%
Q2 2014-16.8%
Q1 2014+6.1%
Q4 2013+1.4%
Q3 2013+7.1%
Q2 2013+2.3%
Q1 2013+7.9%
Q1 2011+0.4%
Q4 2010+0.4%
Q4 2012+5.8%
Q3 2011-20.7%
Q3 2012-16.2%
Q4 2011-0.7%
Q2 2011-0.7%
Q2 2012+0.0%
Q1 2012

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro